Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
Oric Pharmaceuticals Inc (ORIC) - Total Assets
Latest total assets as of September 2025: $431.19 Million USD
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) holds total assets worth $431.19 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oric Pharmaceuticals Inc - Total Assets Trend (2017–2024)
This chart illustrates how Oric Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oric Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oric Pharmaceuticals Inc's total assets of $431.19 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Oric Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oric Pharmaceuticals Inc's current assets represent 95.7% of total assets in 2024, an increase from 88.6% in 2017.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2024, down from 86.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oric Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Oric Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oric Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oric Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oric Pharmaceuticals Inc is currently not profitable relative to its asset base.
Oric Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.65 | 13.15 | 32.96 |
| Quick Ratio | 14.65 | 13.15 | 32.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $275.42 Million | $ 258.18 Million | $ 287.69 Million |
Oric Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Oric Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.39 |
| Latest Market Cap to Assets Ratio | 2.80 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | $274.14 Million |
| Market Capitalization | $768.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oric Pharmaceuticals Inc's assets at a significant premium ( 2.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Oric Pharmaceuticals Inc's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Oric Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of Oric Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $274.14 Million | +7.64% |
| 2023-12-31 | $254.69 Million | +1.73% |
| 2022-12-31 | $250.36 Million | -16.17% |
| 2021-12-31 | $298.64 Million | -0.12% |
| 2020-12-31 | $299.00 Million | +217.77% |
| 2019-12-31 | $94.09 Million | +101.34% |
| 2018-12-31 | $46.73 Million | +55.65% |
| 2017-12-31 | $30.02 Million | -- |